Efficacy of a Multi-Strain Probiotic Formulation in Pediatric Populations: A Comprehensive Review of Clinical Studies

Area of Science:

• Microbiology
• Pediatrics
• Gastroenterology

Background:

• A specific probiotic formulation (Lactobacillus helveticus Rosell®-52, Bifidobacterium infantis Rosell®-33, Bifidobacterium bifidum Rosell®-71) with fructooligosaccharides has been available globally since 2002.
• Clinical research on this probiotic has primarily focused on pediatric populations, with many studies published in non-English journals.

Purpose of the Study:

• To comprehensively review and evaluate the efficacy of this probiotic formulation for various pediatric indications based on existing clinical studies.
• To synthesize evidence from international and Chinese databases regarding the probiotic's impact on diarrhea, immune function, anemia, and other pediatric conditions.

Main Methods:

• Literature searches were conducted across 6 international and Chinese databases for pediatric studies on Biostime® or Probiokid®.
• Twenty-eight relevant studies were identified and categorized by their respective pediatric indications.
• Data on treatment efficacy, risk reduction, and side effects were extracted and analyzed.

Main Results:

• The probiotic significantly improved diarrhea treatment efficacy, reducing unresolved diarrhea by 69% (RR 0.31).
• It enhanced immune defenses, evidenced by improved immune markers and reduced common infection incidence.
• Efficacy was also demonstrated in treating iron deficiency anemia, reducing unresolved anemia by 49% and treatment side effects by 47%.

Conclusions:

• The probiotic formulation is effective in managing pediatric diarrhea and iron deficiency anemia.
• It demonstrates beneficial effects on immune system enhancement and infection prevention in children.
• Further research is warranted for potential applications in oral candidiasis, eczema, and feeding intolerance in premature infants.